We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Review Redefines the Role of MYC in Carcinogenesis

By Biotechdaily staff writers
Posted on 14 Jul 2004
A recent review article that summarized research on the transcription factor MYC revealed that while the MYC protein binds to about 15% of all genes, it does not always activate the genes to which it binds.

N-MYC is a member of the MYC gene family, which contains at least seven closely related genes (C-MYC, N-MYC, L-MYC, P-MYC, R-MYC, S-MYC and B-MYC). More...
The principle functions of MYC are the induction of proliferation and the inhibition of terminal differentiation in certain cells. The human N-MYC gene spans 6-7 kb of genomic DNA and is located on chromosome 2p24.1. The N-MYC proteins have a molecular weight of 65 and 67 kDa.

The gene that codes for synthesis of the MYC protein is the most overexpressed oncogene found in human cancers. Investigators at the Wistar Institute (Philadelphia, PA, USA; www.wistar.upenn.edu) recently reviewed the status of research on MYC for the July 2004 issue of Nature Reviews Cancer. They found that while MYC binds to as many as 15% of all genes, binding alone does not always activate the gene. This observation calls into question long-held assumptions about MYC's functioning and opens new directions for MYC research.

"Previous studies looked at which genes are bound by MYC, and it turns out to be a great percentage of genes--one out of every six,” said senior author Dr. Steven McMahon, an assistant professor at the Wistar Institute. "Our work has extended what these studies hinted at: contrary to what was believed, MYC does not always turn on the genes to which it binds. The implication is that just figuring out which genes bind to MYC will not be enough to tell us what pathways are being activated in cancer. There must be other factors that play a role in whether MYC activates a gene.”



Related Links:
Wistar Institute

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.